T cell costimulatory pathways: Blockade for autoimmunity

Expert Opinion on Biological Therapy

Volumn 3, Issue 2, 2003, Pages 227-236

  Najafian, Nader ^a   Khoury, Samia J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; CD28; Costimulation; CTLA 4; ICOS; PD 1

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN FUSION PROTEIN; HYBRID PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; AUTOIMMUNITY; CELL ACTIVATION; CELL STIMULATION; CLINICAL TRIAL; ENTERITIS; GOODPASTURE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD28; AUTOIMMUNITY; CLINICAL TRIALS; HUMANS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

PURPURA;

EID: 0037393460     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.2.227     Document Type: Review

References (80)

1. REISER H, STADECKER MJ: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N. Engl. J. Med. (1996) 335:1369-1377.
2. SAYEGH MH, TURKA LA: The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med (1998) 338:1813-1821.
3. BRETCHER P, COHN M: A theory of self-nonself discrimination. Science (1970) 169:1042-1049.
4. YAMADA A, SALAMA AD, SAYEGH MH: The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. (2002) 13:559-575.
5. LINSLEY PS, LEDBETTER JA: The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. (1993) 11:191-212.
6. JUNE CH, BLUESTOME JA, NADLER LM, THOMPSON CB: The B7 and CD28 receptor families. Immunol. Today (1994) 15:321-331.
7. NAJAFIAN N, SAYEGH MH: CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Investig. Drugs (2000) 9:2147-2157. A thorough review of CTLA-4-Ig.
8. RILEY J, MAO M, KOBA YASHI S et al.: Modulation of TOR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. USA (2002) 99:11796-11801.
9. DIEHN M, ALIZADEH AA, RANDO OJ et al: Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad Sci. USA (2002) 99:11790-11795. Gene expression studies to evaluate the role of CD28 costimulation in T cell activation.
10. LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174:561-569.
11. WALUNAS TL, BAKKER CY, BLUESTONE JA: CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J. Exp. Med. (1996) 184(1):301] J. Exp. Med. (1996) 183:2541-2550.
12. TIVOL EA, BORRIELLO F, SCHWEIZER AN, LYNCH WP, BLUESTONE JA, SHARPE AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3:541-547.
13. GUINAN EC, GRIBBEN JG, BOUSSIOTIS VA, FREEMAN GJ, NADLER LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 84:3261-3282.
14. WALUNAS TL, LENSCHOW DJ, BAKKER CY et al.: CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1:405-413.
15. LINSLEY PS, GREENE JL, BRADY W, BAJORATH J, LEDBETTER JA, PEACH R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 1:793-801.
16. NOEL PJ, BOISE LH, GREEN JM, THOMPSON CB: CD28 costimulation prevents cell death during primary T cell activation. J. Immunol. (1996) 157:636-642.
17. GIMMI CD, FREEMAN GJ, GRIBBEN JG, GRAY G, NADLER LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA (1993) 90:6586-6590.
18. VAN PARIJS L, ABBAS AK: Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science (1998) 280:243-248.
19. PEREZ VL, VAN PARIJS L, BIUCKIANS A, ZHENG XX, STROM TB, ABBAS AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6:411-417.
20. LUHDER F, HOGLUND P, ALLISON JP, BENOIST C, MATHIS D: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. (1998) 187:427-432.
21. KARANDIKAR NJ, VANDERLUGT CL, WALUNAS TL, MILLER SD, BLUESTONE JA: CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. (1996) 184:783-788.
22. GREENWALD RS, LATCHMAN YE, SHARPE AH: Negative co-receptors on lymphocytes. Curr. Opin. Immunol. (2002) 14:390-396. Excellent review of negative costimulatory pathways on lymphocytes.
23. GUERDER S, PICARELLA DE, LINSLEY PS, FLAVELL RA: Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA (1994) 91:5138-5142.
24. HARLAN DM, HENGARTNER H, HUANG ML et al.: Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. USA (1994) 91:3137-3141.
25. WILLIAMS IR, ORT RJ, KUPPER TS: Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc. Natl. Acad. Sci. USA (1994) 91:12780-12784.
26. WINDHAGEN A, NEWCOMBE J, DANGOND F et al.: Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. (1995) 182:1985-1996.
27. RANHEIM EA, KIPPS TJ: Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis [see comments]. Arthritis Rheum. (1994) 37:1637-1646.
28. SIMON JC, DIETRICH A, MIELKE V et al.: Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases. J. Invest. Dermatol. (1994) 103:539-543.
29. NICKOLOFF BJ, NESTLE FO, ZHENG XG, TURKA LA: T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28. Blood (1994) 83:2580-2586.
30. FIELDS LE, LOH DY: Organ injury associated with extrathymic induction of immune tolerance in doubly transgenic mice. Proc. Natl. Acad. Sci. USA (1992) 89:5730-5734.
31. SCHONRICH G, KALINKE U, MOMBURG F et al.: Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell(1991) 65:293-304.
32. LO D, BURKLY LC, WIDERA G et al.: Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic beta cells. Cell (1988) 53:159-168.
33. LO D, BURKLY LC, FLAVELL RA, PALMITER RD, BRINSTER RL: Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells. J. Exp. Med. (1989) 170:87-104.
34. DURIE FH, FOY TM, MASTERS SR, LAMAN JD, NOELLE RJ: The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today (1994) 15:406-411.
35. HANCOCK WW, SAYEGH MH, ZHENG XG, PEACH R, LINSLY PS, TURKA LA: Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA (1996) 93:13967-13972.
36. RANHEIM EA, KIPPS TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. (1993) 177:925-935.
37. GUO Y, WU Y, SHINDE S, SY MS, ARUFFO A, LIU Y: Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J. Exp. Med (1996) 184:955-961.
38. YELLIN MJ, D'AGATI V, PARKINSON G et al.: Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum. (1997) 40:124-134.
39. WHITMIRE JK, AHMED R: Costimulation in antiviral immunity: differential requirements for CD4(+) and CD8(+) T cell responses. Curr. Opin. Immunol. (2000) 12:448-455.
40. LENSHOW DJ, HEROLD KC, RHEE L et al.: CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes [published erratum appears in Immunity (1997) 6(2):following 215]. Immunity (1996) 5:285-293.
41. CHANG TT, JABS C, SOBEL RA, KUCHROO VK, SHARPE AH: Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J. Exp. Med. (1999) 190:733-740.
42. LONDON CA, LODGE MP, ABBAS AK: Functional responses and costimulator dependence of memory CD4+ T cells. J. Immunol. (2000) 164:265-272.
43. COYLE AJ, GUTIERREZ-RAMOS JC: The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. (2001) 2:203-209.
44. HUTLOFF A, DITTRICH AM, BEIER KC et al.: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 397:263-266. Identifies ICOS as a CD28 homologue on activated human T cells and shows that, in conjuction with a TCR signal, ICOS crosslinking upregulates cytokine production, particularly of IL-10, but not IL-2.
45. DONG C, JUEDES AE, TEMANN UA et al.: ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 409:97-101. Shows that myelin oligodendrocyte glycoprotein-induced EAE is greatly exacerbated in ICOS knockout mice as compared with wild type mice.
46. MCADAM AJ, GREENWALD RJ, LEVIN MA et al.: ICOS is critical for CD40-mediated antibody class switching. Nature (2001) 409:102-105. Shows the crucial role for ICOS in regulating immunoglobulin isotype class switching and in germinal centre formation.
47. TAFURI A, SHAHINIAN A, BLADT F et al.: ICOS is essential for effective T-helper-cell responses. Nature (2001) 409:105-109.
48. SWALLOW MM, WALLIN JJ, SHA WC: B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity (1999) 11:423-432.
49. YOSHINAGA SK, ZHANG M, PISTILLO J et al.: Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int. Immunol. (2000) 12:1439-1447.
50. AICHER A, HAYDEN-LEDBETTER M, BRADY WA et al.: Characterization of human inducible costimulator ligand expression and function. J. Immunol. (2000) 164:4689-4696.
51. AGATA Y, KAWASAKI A, NISHIMURA H et al.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. (1996) 8:765-772.
52. LATCHMAN Y, WOOD CR, CHERNOVA T et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. (2001) 2:261-268. Identifies a B7 homologue as a second receptor for PD-1.
53. FREEMAN GJ, LONG AJ, IWAI Y et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. (2000) 192:1027-1034. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
54. NISHIMURA H, NOSE M, HIAI H, MINATO N, HONJO T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 11:141-151.
55. LECHNER O, LAUBER J, FRANZKE A, SARUKHAN A, VON BOEMER H, BUER J: Fingerprints of anergic T cells. Curr. Biol. (2001) 11:587-595.
56. GAVIN MA, CLARKE SR, NEGROU E, GALLEGOS A, RUDENSKY A: Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat. Immunol. (2002) 3:33-41.
57. HARLAN DM, ABE R, LEE KP, JUNE CH: Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin. Immunol. Immunopathol. (1995) 75:99-111.
58. FINCK BK, LINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA4Ig. Science (1994) 2651:1225-1227.
59. REYNOLDS J, TAM FW, CHANDRAKER A et al.: CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. (2000) 105:643-651.
60. LENSCHOW DJ, HO SC, SATTAR H et al.: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. (1995) 181:1145-1155.
61. RACKE MK, SCOTT DE, QUIGLEY L et al.: Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. (1995) 96:2195-2203.
62. SCHAUB M, ISSAZADEH S, STADLBAUR TH, PEACH R, SAYEGH MH, KHOURY SJ: Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. (1999) 96:158-166.
63. KHOURY SJ, AKALIN E, CHANDRAKER A et al.: CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. (1995) 155:4521-4524.
64. TANG A, JUDGE TA, NICKOLOFF BJ, TURKA LA: Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J. Immunol. (1996) 157:117-125.
65. TANG A, JUDGE TA, TURKA LA: Blockade of CD40-CD40 ligand pathway induces tolerance in murine contact hypersensitivity. Eur. J. Immunol. (1997) 27:3143-3150.
66. KEARNEY ER, WLUNAS TL, KARR RW et al.: Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. (1995) 155:1032-1036.
67. JUDGE TA, WU Z, ZHENG XG, SHARPE AH, SAYEGH MH, TURKA LA: The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol (1999) 162:1947-1951.
68. KUCHROO VK, DAS MP, BROWN JA et al.: B7-1 and B7-2 costimulatory molecules differentially activate the TH1/ TH2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 80:707-718.
69. DAIKH DI, WOFSY D: Effects of anti-B7 monoclonal antibodies on humoral immune responses. J. Autoimmunity (1999) 12:101-108.
70. BALASA B, KRAHL T, PATSTONE G et al.: CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. (1997) 159:4620-4627.
71. GERRITSE K, LAMAN JD, NOELLE RJ et al.: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA (1996) 93:2499-2504.
72. HOWARD LM, MIGA AJ, VANDERLUGT CL et al.: Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. (1999) 103:281-290.
73. KOSHY M, BERGER D, CROW MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. (1996) 98:826-837.
74. DAIKH DI, FINCK BK, LINSLEY PS, HOLLENBAUGH D, WOFSY D: Longterm inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. (1997) 159:3104-3108.
75. SPORICI RA, BESWICK RL, VON ALLMAN C et al.: ICOS ligand costimulation is required for T-cell encephalitogenicity. Clin. Immunol. (2001) 100:277-288.
76. ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. (1999) 103:1243-1252.
77. MORELAND LW, ALTEN R, VAN DEN BOSCH F et al.: Costimulatory blockade in patients with rheumatoid arthritis. Arthritis Rheum. (2002) 46:1470-1479.
78. KAWAI T, ANDREWS D, COLVIN RB, SACHS DH, COSIMI AB: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. (2000) 6:114.
79. KALUNIAN KC, DAVIS JC, MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154. Arthritis Rheum. (2002) 12:3251-3258. First clinical study that evaluates the safety and efficacy of a humanised mAb against CD154 in patients with active SLE.
80. SAYEGH MH: Finally, CTLA4Ig graduates to the clinic. J. Clin. Invest. (1999) 103:1223-1225.